Topics

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

Open deep analysis →

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

Open deep analysis →

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

Open deep analysis →

Does estradiol level affect symptoms and bone health in men on testosterone therapy?

Estradiol in men derives largely from aromatization of testosterone and contributes to bone density and possibly symptom control. Over-suppression with aromatase inhibitors may impair bone health; optimal targets in clinical practice remain debated.

Open deep analysis →

How effective are PDE5 inhibitors for erectile dysfunction?

PDE5 inhibitors substantially improve erectile function versus placebo across broad ED populations, with landmark trials showing clinically meaningful IIEF improvements. On-demand dosing before sexual activity is standard; response rates are high though not universal.

Open deep analysis →

Is daily low-dose tadalafil better than on-demand dosing for erectile dysfunction?

Both daily low-dose and on-demand tadalafil improve erectile function. Daily dosing may improve spontaneity and lower urinary symptom scores in men with comorbid LUTS, while on-demand dosing minimizes drug exposure for men with infrequent sexual activity.

Open deep analysis →

Does testosterone therapy improve erectile function in hypogonadal men?

Testosterone improves sexual desire and some erectile function endpoints in men with confirmed hypogonadism, but effects are smaller than PDE5 inhibitors for vascular erectile dysfunction. Treat documented deficiency when indicated; do not rely on testosterone alone for moderate-to-severe ED without evaluating PDE5 therapy.

Open deep analysis →

Are PDE5 inhibitors safe for cardiovascular disease in men with erectile dysfunction?

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.

Open deep analysis →

Does menopausal hormone therapy prevent osteoporosis and fractures?

Estrogen-based therapy reduces bone loss and fracture risk in postmenopausal women, with benefit most established during early postmenopause. Guidelines support HRT for fracture prevention primarily when indicated for vasomotor symptoms or in high-risk women.

Open deep analysis →

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

Open deep analysis →

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

Open deep analysis →

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

Open deep analysis →

Should subclinical hypothyroidism be treated with levothyroxine?

The TRUST trial found no meaningful symptom or quality-of-life benefit from levothyroxine in older adults with subclinical hypothyroidism. Treatment may still be considered with very high TSH, pregnancy plans, or specific clinical contexts.

Open deep analysis →

What factors interfere with levothyroxine absorption?

Levothyroxine absorption is reduced by concurrent iron, calcium, PPIs, and some foods including coffee and fiber. Consistent fasting dosing separated from interfering substances improves TSH stability.

Open deep analysis →

Is desiccated thyroid extract superior to levothyroxine for hypothyroidism?

Levothyroxine is standard first-line therapy with the strongest outcome evidence. Desiccated thyroid extract lacks modern RCT data demonstrating superiority and has variable hormone content between batches.

Open deep analysis →

Does treated hypothyroidism fully explain difficulty losing weight?

Hypothyroidism can contribute to weight gain, but levothyroxine normalization typically yields modest weight loss rather than resolving obesity. Persistent weight difficulty usually involves additional metabolic and behavioral factors.

Open deep analysis →

Should adults take statins for primary cardiovascular prevention?

Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.

Open deep analysis →

Should aspirin be used for primary cardiovascular prevention?

Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.

Open deep analysis →

Does elevated lipoprotein(a) independently increase cardiovascular risk?

Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.

Open deep analysis →

Is ApoB more useful than LDL-C for cardiovascular risk prediction?

Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.

Open deep analysis →

Do GLP-1 receptor agonists reduce major cardiovascular events?

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

Open deep analysis →

How does tirzepatide compare with semaglutide for weight loss?

Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.

Open deep analysis →

Do patients regain weight after stopping GLP-1 therapy?

Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.

Open deep analysis →

Does GLP-1 treatment cause meaningful muscle loss?

GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.

Open deep analysis →

When is growth hormone replacement appropriate in adults?

Growth hormone replacement is evidence-supported for adults with confirmed GH deficiency from pituitary disease, improving body composition and quality of life. Use in healthy aging or performance enhancement lacks safety and efficacy evidence.

Open deep analysis →

Does vitamin D supplementation reduce mortality or major disease?

Meta-analyses show vitamin D supplementation does not significantly reduce all-cause mortality in unselected populations. Targeted repletion may benefit those with documented deficiency.

Open deep analysis →

Does magnesium supplementation improve metabolic health markers?

Trials in deficient or at-risk individuals show modest improvements in some glycemic and blood pressure markers, but routine supplementation for metabolic disease prevention is not strongly supported in general populations.

Open deep analysis →

Does DHEA supplementation improve health outcomes in aging adults?

DHEA raises circulating androgens and estrogens modestly but lacks robust outcome trial evidence for cardiovascular, cognitive, or mortality benefit in healthy aging adults without documented deficiency.

Open deep analysis →